Travel Tip
 Conf TL
 RF Club
 PNR Ref
 PNR Req
 Blank PNRs
 FM Alert
 FM Approval
News Super Search
Posting Date From:
Posting Date To:
IR Press Release:


RailFanning is a gift you give yourself. - Varun

Full Site Search
  Full Site Search  
Sat Jan 16 12:26:38 IST
Advanced Search
<<prev entry    next entry>>
News Entry# 422596
Oct 24 2020 (10:38) Hyderabad startup's 'CoronAid' promises immunity against COVID-19 (

News Entry# 422596  Blog Entry# 4757224   
  Past Edits
This is a new feature showing past edits to this News Post.
Saturday, Oct 24, 2020 | Last Update : 10:38 AM IST
Hyderabad: In a major fillip to the fight against the dreaded coronavirus, a city-based start-up incubated at the centre for cellular and molecular biology (CCMB) has developed a novel nutraceutical which, they claim, will boost immunity.
The start-up, Clone Deals, incubated at Atal incubation centre-CCMB (AIC-CCMB), has developed ‘CoronAid’, a food supplement made from a mushroom (Cordyceps militaris) that grows in the Himalayan region and is known for its immune-boosting and anti-oxidant components.  With the results of the clinical trials, the product
is expected to be available from December 2020 in most cities and towns.
Collaborating with another city-based company, Ambrosia food company, Clone Deals has developed a combination of the mushroom powder with curcumin, an active ingredient in turmeric to make CoronAid anti-viral immunity booster oral suspension.
Cordycepin in the mushroom powder is known to prevent the formation of new DNA and RNA strands. Clone Deals has collaborated with scientists from CCMB to establish the potency of cordycepin in stopping the growth of the Covid-19-causing coronavirus in a cell-culture system. The studies show that cordycepin inhibits the multiplication of coronavirus.
Clone Deals has expertise in large-scale production of the mushroom in a controlled environment for its medicinal use. Currently, the team has obtained FSSAI approval to market it and has submitted it to government of India for conducting clinical trials to establish the safety of their formulation with three All India institutes of medical sciences in Nagpur, Navi Mumbai and Bhopal.
Dr. Prakash Ayodhya Pandem and M. Ateek Patel of Clone Deals hope that CoronAid would be a new year’s gift to the world and add considerable protection against the virus. CCMB director, Dr. Rakesh Mishra, expressed his pleasure in supporting a start-up focused on developing indigenous natural products and adding value by establishing its scientific basis.
Dr. Madhusudhana Rao, CEO of AIC-CCMB, said that providing necessary facilities and scientific support to start-ups like Clone Deals is critical for validation of their technology and market-readiness.
Scroll to Top
Scroll to Bottom
Go to Mobile site
Important Note: This website NEVER solicits for Money or Donations. Please beware of anyone requesting/demanding money on behalf of IRI. Thanks.
Disclaimer: This website has NO affiliation with the Government-run site of Indian Railways. This site does NOT claim 100% accuracy of fast-changing Rail Information. YOU are responsible for independently confirming the validity of information through other sources.
India Rail Info Privacy Policy